21:13 , Sep 12, 2018 |  BC Extra  |  Preclinical News

Genentech develops antibiotic against multidrug resistant Gram-negatives

Genentech Inc. researchers have developed arylomycin derivatives with potent activity against Gram-negative bacteria, including multidrug resistant (MDR) strains. The small molecule could represent a notable step forward against Gram-negative bacteria, for which no new class...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
19:48 , Aug 23, 2018 |  BC Extra  |  Tools & Techniques

Computational tool prospectively predicts resistance to cancer drugs

An Institute of Cancer Research team has developed a computational prediction tool that can predict which resistant mutations will develop in response to cancer drugs before a patient takes the drug. The results suggest the...
22:49 , Aug 10, 2018 |  BC Extra  |  Preclinical News

New approach could identify Ras-blocking small molecules

With an eye on historically undruggable cancer target Ras, a University of Oxford team and colleagues devised a way to find small molecules that have the same qualities as Ras inhibitors too large to access...
06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
22:43 , Aug 6, 2018 |  BC Extra  |  Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
19:29 , Aug 1, 2018 |  BC Innovations  |  Emerging Company Profile

Connecting the DotBodies

Cancer play DotBio Pte. Ltd. launched this week with a screening platform to discover and develop products based on humanized domain antibodies that could be more stable and easier to manufacture than other domain antibodies. DotBio...
14:45 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Global Blood reports Phase III sickle cell data that could support accelerated approval of voxelotor

Global Blood Therapeutics Inc. (NASDAQ:GBT) reported data from Part A of the Phase III HOPE trial that it believes could support accelerated approval of voxelotor (formerly GBT440) to treat sickle cell disease. The company said voxelotor...
00:43 , Jun 29, 2018 |  BC Innovations  |  Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
22:51 , Jun 28, 2018 |  BC Innovations  |  Translation in Brief

Conformist nanobodies

A University of Zurich team in collaboration with Roche has figured out how to make fully synthetic nanobodies that can bind to membrane proteins in specific conformations -- simultaneously opening up new target space for...